What is Liquid Biopsy?  

    Cancer detection and monitoring method

    Liquid Biopsy, also known as fluid biopsy, is a significant branch of in vitro diagnosis that is primarily based on blood or other body fluid for disease analysis and monitoring, such as cancer. With a simple blood draw, circulating tumor biomarkers in the blood sample provide information on tumor progression and treatment efficacy, and guiding personalized precision medication direction. Compared with traditional tissue biopsy, liquid biopsy has provided additional benefits of real-time monitoring, avoid unrepresentative sampling in heterogenous tumor, and provides comprehensive clinical information.

    Liquid Biopsy is a branch of in vitro diagnostics that analyses and diagnoses diseases such as cancer through the use of body liquids like blood or urine. It was rated as one of the “Breakthrough Technologies 2015” by MIT Technology Review.

    Compared to traditional tissue biopsy, liquid biopsy is equipped with unique advantages like real-time monitoring, ability to overcome tumor heterogeneity, and comprehensive diagnostic information. Currently, in clinical researches, liquid biosy mainly includes tests for CTC (Circulating Tumor Cell), ctDNA (Circulating Tumor DNA), exosomes, and Circulating miRNA etc. In comparison to traditional methods like observation of clinical symptoms or diagnostic imaging, using liquid biopsy can predict the risk of cancer earlier, enabling “Early discovery, early screening, early treatment”.

What is Circulating miRNA?

microRNAs or miRNAs are small RNA molecules that are non-coding and have important effects on gene expression, often inhibitory.  By binding to mRNAs in the cells, the microRNAs inhibit DNA functioning, thus affecting important life functions in a cell. In many cancer types, miRNAs production is upregulated, converting an ordinary cell into a cancerous one. Additionally, these miRNAs can be transported outside the cell, in the tumour environment, in sacs/vesicles called 'exosomes'. The presence of a high number of exosomal miRNAs has been associated with the spread of certain types of cancer in the body. Isolation and detection of miRNAs from a patient’s blood can help in early cancer diagnosis, without the need for invasive surgeries.

What is Circulating Tumor Cell (CTC)?

Circulating tumor cell (CTCs) are the cancer cells that have detached from the primary tumor or metastatic tumor into circulatory system during tumor progression or metastases. CTC provides comprehensive information of cancer in cellular, genetics and protein levels. Hence, CTC detection is an effective tool for earlier detection, evaluation of therapeutic efficacy, individual precision medicine selection, drug resistance detection, earlier tumor recurrence evaluation and real-time monitoring of cancer.

How can we detect CTCs in blood?

Cellomics CTC detection Platform - New generation of CTC viable Cell Sorting.

The CTC detection platform has employed the leading microfluidic chip technology that select CTCs extensively by cell size, cell shape and multiple surface biomarkers. This technology has combined the physical, chemical and biological properties of CTCs to uphold the high sensitivity, high specificity and high accuracy of CTC detection.


Cellomics is the first biotechnology company to launch “Comprehensive Solution for Liquid Biopsy” internationally. We broke through the bottleneck of CTC detection and created a new era of CTC detection technology with high specificity, strong pertinence and high sensitivity, allowing screening and enriching CTCs. Such detection technology allows us to capture comprehensive information of cancer cells and accomplishing precise diagnosis and real-time monitoring.

Based in the Greater Bay Area, Cellomics has gained worldwide recognition and possesses internationally advanced microfluidic chip technology and nucleic acid detection technology with independent intellectual property rights. Our core technology “Microfluidics-based Platform for Cell and Biomolecule Detection”earned the 2019 Deloitte Hong Kong Rising Star Awards, Gold prize in 2019 Asia International Innovation Invention Award, 2019 Outstanding Biotechnology Invention Award, the 47th Geneva International Invention Expo Gold Medal in 2019, Wuxi PharmaTech Life Science and Chemistry Awards in 2016, Natural Science Award by the Ministry of Education in 2015 etc. We have also published numerous papers in internationally renowned magazines and hold patents for multiple inventions.

In the future, Cellomics will continue our corporate ethos of “Top Quality, Scientific Management, Professional Focus, Best of the Best”, and concentrate in our research to obtain complete cancer information through tumor cells, aiming to achieve early screening of cancer and assist cancer patients in defeating the disease.

About Cellomics

Cellomics International Limited (“Cellomics”) was incorporated in Hong Kong in 2018, and its Shenzhen subsidiary, Cellomics (Shenzhen) Co., Ltd. is located in Haikexing Hi-Tech Industrial Park in Pingshan, Shenzhen. Cellomics is a high-tech life-sciences enterprise which focuses on integrating research and development of tumor liquid biopsy technology, products transformation, and gene detection services.

  • We are dedicated to providing high-efficiency and accurate individualized liquid biopsy products and services for cancer patients. We independently and fully own the intellectual property rights to advanced microfluidic chip technology and nucleic acid detection technology, which we utilize to provide comprehensive, high-precision, high-throughput and low-cost tumor liquid biopsy diagnostic solutions, services and products, including circulating tumor cell sorting chips and device, droplet digital PCR chips and devices, ctDNA and miRNA detection kit products for tumor liquid biopsy, etc. 

  • Cellomics also operates a "Medical Laboratory" and "CTC detection Laboratory". We have become a comprehensive service platform integrating clinical testing services, scientific research and development. We are committed to providing precise detection and personalized drug guidance technical services, and aim to be a key partner of clinical medical units and scientific research institutions, benefiting the large number of patients suffering from chronic diseases such as cancer, cardiovascular disease and diabetes.

  • Our future development / pipeline projects will combine with the latest international academic research to extend our products / services range to include the precise treatment and monitoring of a variety of major high-incidence chronic diseases.



CTC 100 Sorter





The Team




Contact Us

Email: info@cellomicsbio.com

Tel: +86-0755-28378001

Copyright © 2020 Cellomics All Rights Reserved

Copyright © 2020 Cellomics All Rights Reserved